



Synthesis and Characterization of Some New N-(Substituted 4-Methylene-2-oxo-4H-benzo[e][1,3]oxazin-3-yl)isonicotinamide

ABDULLAH S. AL-BOGAMI

Department of Chemistry, King Abdulaziz University, P.O. Box 15758 Jeddah 21454, Saudi Arabia

*Corresponding author: Fax: +966 26914286; Tel: +966 554433416; E-mail: chem_org@hotmail.com

(Received: 26 August 2010;

Accepted: 9 March 2011)

AJC-9725

The N-(substituted 4-methylene-2-oxo-4H-benzo[e][1,3]oxazin-3-yl)isonicotinamide were synthesized by condensation of isonicotinic acid hydrazide derivatives with triphosgene. The structures of all the synthesized compounds have been elucidated by microanalysis and IR, NMR, MS spectroscopic measurements.

Key Words: Isoniazid, 2-Hydroxyacetophenone derivative, Hydrazides, Microwave irradiation, Triphosgene, 1,3-Benzoxazines.

INTRODUCTION

Tuberculosis is a chronic infectious disease caused by mycobacteria of the 'tuberculosis complex', including *Mycobacterium bovis*, *Mycobacterium africanum* and *Mycobacterium tuberculosis*. Tuberculosis now kills more adults than all other infectious diseases combined. Active tuberculosis is usually treated with isoniazid in association with one or more other anti tuberculosis drugs but multi-drug resistant tuberculosis (MDR-TB) and recently extensively drug resistant tuberculosis (XDR-TB) has become a serious and unsolved public health problem¹⁻⁶. Isoniazid discovered in 1952 is still the most important drug for treatment of tuberculosis. The full therapeutic possibilities of hydrazides were realized after the discovery of isoniazid. Hydrazides and their derivatives have been described as useful synthons of various heterocyclic rings⁷. A large number of hydrazides and their derivatives are reported to possess a broad spectrum of biological activities^{8,9}. Thus, these were found to be useful especially in the treatment of inflammatory and autoimmune diseases, osteoarthritis, respiratory diseases, tumors, cachexia, cardiovascular diseases, fever, hemorrhage and sepsis¹⁰. Hydrazides and derivatives exhibited antifungal⁸, psychotropic⁹, antituberculous¹¹, antiparasite^{8,12}, bacteriostatic¹³⁻¹⁶, antiviral¹⁶, insecticidal⁹ and anticancer¹⁷ activities. Much research has been carried out with the aim to finding therapeutic values of 1,3-benzoxazines moiety since their discovery. A large number of substituted 1,3-benzoxazines derivatives are prepared and tested for variety of biological activities. Such as antimycobacterial activity¹⁸. We have recently reported the use of triphosgene for the

cyclization of hydrazones of 2-acetyl-1-naphthol and 1-acetyl-2-naphthol to give naphthoxazine and spiro naphthoxazine¹⁹. Here we report the cyclization reaction of hydrazides with triphosgene.

EXPERIMENTAL

Melting points are uncorrected and were determined on Gallenkamp-melting point apparatus. IR spectra were recorded on a Perkin-Elmer 883 spectrophotometer. NMR spectra were recorded on Jeol ECP 400 (400 MHz) in CDCl₃ and expressed as δ in ppm. Mass spectra were recorded on Shimadzu QP-5050A GC/MS system. Microwave irradiations were carried out in a domestic microwave oven (Panasonic model N-N-20002 W) output of 1000 W. TLC was performed on (TLC plates silica gel 60 F₂₄₅ pre-coated 20 cm \times 20 cm layer thickness 0.25 mm).

General procedure for the preparation of hydrazides (3a-e): A solution of the appropriate isonicotinic acid hydrazide (isoniazid) (3.65 mmol), 2-hydroxy-acetophenone (7.28 mmol) in absolute ethanol (3 mL). After irradiation in a microwave oven at 250 Watt for 2-3 min. The separated solid was collected by filtration and recrystallized from ethanol.

Isonicotinic acid[1-(2-hydroxy-phenyl)ethylidene]-hydrazide (3a): This compound was prepared from 2-hydroxy-acetophenone and isoniazid. Yield ca. 94 %, yellowish white powder, m.p. 237-238 °C; IR (KBr, ν_{\max} , cm⁻¹): 1551 (C=N), 1700 (C=O), 3235 (NH), 3345 (OH); ¹H NMR (400 MHz, CDCl₃): δ 2.47 (s, 3H, CH₃), 6.86-7.63 (m, 4H, H_{aromatic}), 7.83 (d, 2H, *J* = 5.88 Hz, 3,5-pyridine-H), 8.77 (d, 2H, *J* = 5.84 Hz, 2,6-pyridine-H), 11.57 (s, 1H, NH), 13.20 (s, 1H, OH); ¹³C

NMR (100 MHz, CDCl₃): δ 14.81, 117.89, 119.14, 119.75, 122.55 (C_{3,5}-pyridine), 129.25, 132.10, 140.64, 150.71 (C_{2,6}-pyridine), 155.29, 158.54 (C=N), 163.53 (C=O); MS: m/z (%) 255 (M⁺, 92), 241, 240, 231, 156, 114, 109, 91, 81, 65, 51, 29; Anal. calcd. (%) for C₁₄H₁₃N₃O₂: C, 65.87; H, 5.13; N, 16.46. Found (%): C, 65.52; H, 5.22; N, 16.38.

Isonicotinic acid [1-(5-chloro-2-hydroxy-phenyl)-ethylidene]hydrazide (3b): This compound was prepared from 5-chloro-2-hydroxyacetophenone and isoniazid. Yield *ca.* 91 %, yellowish white powder, m.p. 234–235 °C; IR (KBr, ν_{\max} , cm⁻¹): 3351 (OH), 3216 (NH), 1557 (C=N), 1705 (C=O); ¹H NMR: 2.54 (s, 3H, CH₃), 6.94–7.66 (m, 3H, H_{aromatic}), 7.85 (d, 2H, *J* = 5.84 Hz, 3,5-pyridine-H), 8.80 (d, 2H, *J* = 5.88 Hz, 2,6-pyridine-H), 11.67 (s, 1H, NH), 13.29 (s, 1H, OH); ¹³C NMR: 14.96, 119.72, 121.27, 122.60 (C_{3,5}-pyridine), 122.74, 128.50, 131.59, 140.51, 150.73 (C_{2,6}-pyridine), 158.02, 158.54 (C=N), 163.71 (C=O); MS: m/z (%) 291 (M + 2, 92), 289 (M + 1, 49), 276, 241, 231, 156, 114, 109, 91, 81, 65, 51, 29; Anal. calcd. (%) for C₁₄H₁₂N₃O₂Cl: C, 58.04; H, 4.17; N, 14.50. Found (%): C, 58.50; H, 4.10; N, 14.26.

Isonicotinic acid [1-(3,5-dichloro-2-hydroxy-phenyl)-ethylidene]hydrazide (3c): This compound was prepared from 3,5-di-chloro-2-hydroxyacetophenone and isoniazid. Yield *ca.* 86 %, brown powder, m.p. 287–288 °C; IR (KBr, ν_{\max} , cm⁻¹): 3344 (OH), 3075 (NH), 1649 (C=N), 1693 (C=O); ¹H NMR: 2.51 (s, 3H, CH₃), 7.64–7.70 (m, 2H, H_{aromatic}), 7.87 (d, 2H, *J* = 5.88 Hz, 3,5-pyridine-H), 8.81 (d, 2H, *J* = 5.88 Hz, 2,6-pyridine-H), 11.67 (s, 1H, NH), 13.29 (s, 1H, OH); ¹³C NMR: 15.01, 119.75, 121.20, 122.64 (C_{3,5}-pyridine), 127.59, 131.25, 140.50, 150.76 (C_{2,6}-pyridine), 158.34 (C=N), 163.98 (C=O); MS: m/z (%) 327 (M + 4, 8), 325 (M + 2, 4), 323 (M + 1, 9), 310, 278, 265, 182, 109, 91, 81, 65, 51, 29; Anal. calcd. (%) for C₁₄H₁₁N₃O₂Cl₂: C, 51.87; H, 3.42; N, 12.96. Found (%): C, 51.23; H, 3.16; N, 12.56.

Isonicotinic acid [1-(2-hydroxy-5-methyl-phenyl)-ethylidene]hydrazide (3d): This compound was prepared from 2-hydroxy-5-methylacetophenone and isoniazid. Yield *ca.* 91 %, pale yellow powder, m.p. 163–165 °C; IR (KBr, ν_{\max} , cm⁻¹): 3340 (OH), 3220 (NH), 1650 (C=N) 1698 (C=O); ¹H NMR: 2.27 (s, 3H, CH₃C=N), 2.51 (s, 3H, CH₃), 6.81–7.45 (m, 3H, H_{aromatic}), 7.85 (d, 2H, *J* = 5.88 Hz, 3,5-pyridine-H), 8.80 (d, 2H, *J* = 5.88 Hz, 2,6-pyridine-H), 11.57 (s, 1H, NH), 12.98 (s, 1H, OH); ¹³C NMR: 14.86 (CH₃C=N), 20.76, 117.71, 119.41, 125.57 (C_{3,5}-pyridine), 127.59, 129.29, 32.78, 140.74, 150.73 (C_{2,6}-pyridine), 157.11, 160.06 (C=N), 163.50 (C=O); MS: m/z (%) 269 (M + 1, 100), 252, 241, 231, 156, 114, 109, 91, 81, 65, 51, 29; Anal. calcd. (%) for C₁₅H₁₅N₃O₂: C, 66.90; H, 5.61; N, 15.60. Found (%): C, 66.21; H, 5.26; N, 15.10.

Isonicotinic acid [1-(2-hydroxy-5-methoxy-phenyl)-ethylidene]hydrazide (3e): This compound was prepared from 2-hydroxy-5-methoxyacetophenone and isoniazid. Yield *ca.* 89 %, yellow powder, m.p. 248–251 °C; IR (KBr, ν_{\max} , cm⁻¹): 3331 (OH), 3229 (NH), 1659 (C=N) 1701 (C=O); ¹H NMR: 2.54 (s, 3H, CH₃), 3.79 (s, 3H, OCH₃), 6.85–7.15 (m, 3H, H_{aromatic}), 7.86 (d, 2H, *J* = 5.88 Hz, 3,5-pyridine-H), 8.80 (d, 2H, *J* = 5.88 Hz, 2,6-pyridine-H), 11.56 (s, 1H, NH), 12.66 (s, 1H, OH); ¹³C NMR: 15.00, 56.15 (OCH₃), 113.57, 118.49, 118.57, 119.83, 122.57 (C_{3,5}-pyridine), 140.71, 150.73 (C_{2,6}-pyridine), 152.04, 153.24, 159.70 (C=N), 163.53 (C=O); MS: m/z (%)

285 (M + 1, 64), 254, 241, 231, 156, 114, 109, 91, 81, 65, 51, 29; Anal. calcd. (%) for C₁₅H₁₅N₃O₃: C, 65.45; H, 5.49; N, 17.43. Found (%): C, 65.20; H, 5.20; N, 17.49.

General procedure for the preparation of (4a-e): A solution of the appropriate hydrazide (**3a**) (3 mmol) and 1 mL of triethylamine in 25 mL of dichloromethane was stirred under nitrogen atmosphere. Triphosgene (1.5 mmol) in 10 mL of dichloromethane was added drop wise over a period of 15 min. The mixture was stirred at room temperature for 1 h and then refluxed for 3 h. Water was added, the organic layer was separated followed by extraction of the aqueous layer with dichloromethane (30 mL). The combined organic layers were dried over magnesium sulfate and evaporated to dryness. The resulting solid was crystallized from ethyl ether.

N-(4-Methylene-2-oxo-4H-benzo[e][1,3]oxazin-3-yl)-isonicotinamide (4a): This compound was prepared from **3a**. Yield *ca.* 79 %, colourless solid, m.p. 210–212 °C; IR (KBr, ν_{\max} , cm⁻¹): 1612 (=CH₂), 1673 (C=O_{amide}), 1726 (C=O), 3310 (NH); ¹H NMR (400 MHz, CDCl₃): δ 5.04 (d, *J* = 2.5 Hz, 1H), 5.10 (d, *J* = 2.5 Hz, 1H), 7.20–7.90 (4H, H_{aromatic}), 8.23 (d, 2H, *J* = 5.90 Hz, 3,5-pyridine-H), 9.00 (d, 2H, *J* = 5.90 Hz, 2,6-pyridine-H), ¹³C NMR (100 MHz, CDCl₃): δ 88.56, 111.51, 120.69, 122.94, 125.18, 127.47, 128.12, , 129.31, 134.67, 138.69, 146.16, 148.05, 164; MS: m/z (%) 281 (M + 1, 64), 254, 236, 241, 231, 156, 114, 109, 106, 91, 81, 65, 51, 29; Anal. calcd. (%) for C₁₅H₁₁N₃O₃: C, 64.05; H, 3.94; N, 14.94. Found (%): C, 64.20; H, 3.22; N, 14.41.

N-(6-Chloro-4-methylene-2-oxo-4H-benzo[e][1,3]oxazin-3-yl)isonicotinamide (4b): This compound was prepared from **3b**. Yield *ca.* 66 %, colourless solid, m.p. 280–282 °C; IR (KBr, ν_{\max} , cm⁻¹): 16110 (=CH₂), 1670 (C=O_{amide}), 1722 (C=O), 3311 (NH); ¹H NMR (400 MHz, CDCl₃): δ 5.05 (d, *J* = 2.5 Hz, 1H), 5.10 (d, *J* = 2.5 Hz, 1H), 7.28–7.93 (3H, H_{aromatic}), 8.21 (d, 2H, *J* = 5.90 Hz, 3,5-pyridine-H), 9.01 (d, 2H, *J* = 5.90 Hz, 2,6-pyridine-H), ¹³C NMR (100 MHz, CDCl₃): δ 88.52, 111.54, 121.01, 122.10, 124.11, 127.27, 128.22, , 129.33, 134.77, 138.70, 146.26, 148.06, 164.11; MS: m/z (%) 317 (M + 2, 23), 315 (M + 1, 77), 280, 254, 236, 241, 231, 156, 114, 109, 106, 91, 81, 65, 51, 29; Anal. calcd. (%) for C₁₅H₁₀N₃O₃Cl: C, 57.07; H, 3.19; N, 13.31. Found (%): C, 57.20; H, 3.20; N, 13.31.

N-(6,8-Dichloro-4-methylene-2-oxo-4H-benzo[e][1,3]oxazin-3-yl)isonicotinamide (4c): This compound was prepared from **3c**. Yield *ca.* 64 %, white powder, m.p. 190–193 °C; IR (KBr, ν_{\max} , cm⁻¹): 1609 (=CH₂), 1674 (C=O_{amide}), 1725 (C=O), 3312 (NH); ¹H NMR (400 MHz, CDCl₃): δ 5.05 (d, *J* = 2.5 Hz, 1H), 5.112 (d, *J* = 2.5 Hz, 1H), 7.27–7.95 (2H, H_{aromatic}), 8.20 (d, 2H, *J* = 5.90 Hz, 3,5-pyridine-H), 9.01 (d, 2H, *J* = 5.90 Hz, 2,6-pyridine-H), ¹³C NMR (100 MHz, CDCl₃): δ 87.98, 111.74, 121.08, 122.13, 124.13, 127.29, 128.20, 129.38, 134.71, 138.77, 146.29, 148.09, 164.41; MS: m/z (%) 351 (M + 2, 44), 349 (M + 1, 55), 314, 280, 254, 241, 231, 156, 114, 109, 106, 91, 81, 65, 51; Anal. calcd. (%) for C₁₅H₉N₃O₃Cl₂: C, 51.45; H, 2.59; N, 12.00. Found (%): C, 51.21; H, 2.60; N, 12.05.

N-(6-Methyl-4-methylene-2-oxo-4H-benzo[e][1,3]oxazin-3-yl)isonicotinamide (4d): This compound was prepared from **3d**. Yield *ca.* 72 %, white powder, m.p. 290–291 °C; IR (KBr, ν_{\max} , cm⁻¹): 1615 (=CH₂), 1677 (C=O_{amide}),

1728 (C=O), 3316 (NH); ¹H NMR (400 MHz, CDCl₃): δ 5.05 (d, *J* = 2.5 Hz, 1H), 5.112 (d, *J* = 2.5 Hz, 1H), 7.33-7.92 (3H, H_{aromatic}), 8.27 (d, 2H, *J* = 5.90 Hz, 3,5-pyridine-H), 9.12 (d, 2H, *J* = 5.90 Hz, 2,6-pyridine-H), ¹³C NMR (100 MHz, CDCl₃): δ 88.22, 111.64, 121.11, 122.18, 124.23, 127.33, 128.45, 129.70, 134.64, 138.69, 146.31, 148.12, 164.12; MS: *m/z* (%) 295 (M + 1, 40), 280, 254, 241, 232, 156, 114, 109, 106, 91, 81, 65, 29; Anal. calcd. (%) for C₁₆H₁₃N₃O₃: C, 65.08; H, 4.44; N, 14.23. Found (%): C, 65.23; H, 4.61; N, 14.15.

N-(6-Methoxy-4-methylene-2-oxo-4*H*-benzo[e][1,3]-oxazin-3-yl)isonicotinamide (4e): This compound was prepared from **3e**. Yield *ca.* 74 %, white powder, m.p. 223-225 °C; IR (KBr, ν_{max}, cm⁻¹): 1614 (=CH₂), 1679 (C=O_{amide}), 1721 (C=O), 3310 (NH); ¹H NMR (400 MHz, CDCl₃): δ 5.05 (d, *J* = 2.5 Hz, 1H), 5.11 (d, *J* = 2.5 Hz, 1H), 7.35-7.94 (3H, H_{aromatic}), 8.20 (d, 2H, *J* = 5.90 Hz, 3,5-pyridine-H), 9.15 (d, 2H, *J* = 5.90 Hz, 2,6-pyridine-H), ¹³C NMR (100 MHz, CDCl₃): δ 88.21, 111.63, 121.10, 122.19, 124.11, 127.13, 128.10, 129.71, 134.60, 138.01, 146.82, 148.11, 164.92; MS: *m/z* (%) 311 (M + 1, 40), 310, 254, 241, 232, 156, 114, 109, 106, 91, 81, 29; anal. calcd. (%) for C₁₆H₁₃N₃O₄: C, 61.73; H, 4.20; N, 13.50. Found (%): C, 61.43; H, 4.51; N, 13.15.

RESULTS AND DISCUSSION

A series of hydrazides **3** was prepared from the reaction of isonicotinic acid hydrazide (isoniazid) **1** with 2-hydroxyacetophenone derivative **2** under microwave irradiation (**Scheme-I**).

Synthesis of hydrazides **3** compounds **3a-e** (Table-1) show in their IR spectra absorbance for the hydroxyl group at about 3350 cm⁻¹. Other major bands at 3235, 1700 and 1550 cm⁻¹ which are attributed to ν(NH), ν(C=O) and ν(C=N), respectively. In ¹H NMR spectra the methyl group appears as a singlet about δ = 2.55 ppm. The signals at about δ = 13.20 ppm and δ = 11.57 ppm represent OH and NH, respectively. Upon addition of D₂O the intensities of both OH and NH protons significantly

R ₁	R ₂	Product	Yield (%)
H	H	3a	94
H	Cl	3b	91
Cl	Cl	3c	86
H	CH ₃	3d	91
H	OCH ₃	3e	89



decrease, confirming the assignment. The ¹³C NMR spectra showed the methyl group at 14.81 ppm. The signals at δ = 163.71 ppm and δ = 158.54 ppm represent C=O and C=N, respectively.


Although **3** could exist as E or Z isomers, it was used in the next step without investigating its stereochemistry. Previous work on the cyclization of similar hydrazones to give the benzotriazepine ring system did not investigate the stereochemistry of the hydrazones²⁰⁻²². Nevertheless, in present case, if the cyclization proceeds *via* the enamine form as shown in **Scheme-III**, the C=N will be broken and its stereochemistry will be lost.

Treatment of the hydrazides **3a-e** with triphosgene in dichloromethane in the presence of triethylamine gave the N-(substituted 4-methylene-2-oxo-4*H*-benzo[e][1,3]oxazin-3-yl)isonicotinamide **4a-e** (**Scheme-II**, Table-2).

The cyclization of **3** to **4** did not proceed to form a seven membered ring (benzoxadiazepine) in a similar manner to that previously reported for the cyclization of hydrazones of 2-aminobenzophenone into benzotriazepines with phosgene and paraformaldehyde^{20,22}. The methyl group in **3** is involved in the cyclization step *via* the formation of the enamine form of **3** which reacts with triphosgene to give the six membered ring product **4** rather than the seven membered ring (benzoxadiazepine) (**Scheme-III**). A similar cyclization across the enol form of acetophenone has previously been reported²².

Compounds of type **4** show in their IR spectra absorbance for the exocyclic double bond ν(=CH₂) at 1612 cm⁻¹. Another





Scheme-III

 TABLE-2
 PER CENT YIELD OF THE PRODUCTS 4a-e

Reagent	Product	Yield* (%)
 3a	 4a	79
 3b	 4b	66
 3c	 4c	64
 3d	 4d	72
 3e	 4e	74

*Yields refer to isolated products.

important band occurs at 1673 cm^{-1} attributed to carbonyl-amide carbonyl and NH-amide absorption bands appear at 1726 and 3310 cm^{-1} , respectively. The protons of the latter group appear as two doublets at $\delta = 5.04$ and 5.10 ppm with coupling constants of about 2.5 Hz in the ^1H NMR spectra. Furthermore, the ^{13}C NMR spectra show a distinct absorbance for the exocyclic methylene group at about 88.56 ppm , which is in agreement with previous studies on related compounds^{21,23-25}.

ACKNOWLEDGEMENTS

The author is highly thankful to Dr. Hamad Z. Alkhatlan, Professor of Chemistry Department, King Saud University for valuable suggestions and guidance.

REFERENCES

- M.A. Aziz, A. Wright, A. Laszlo, A. De Muynck, F. Portaels, A. Van Deun, C. Wells, P. Nunn, L. Blanc and M. Raviglione, *Lancet*, **368**, 2142 (2006).
- M.C. Raviglione and I.M.N. Smith, *Engl. J. Med.*, **356**, 656 (2007).
- K.F. Pasqualoto, E.I. Ferreira, O.A. Santos-Filho and A.J. Hopfinger, *J. Med. Chem.*, **47**, 3755 (2004).
- C.J. Wei, B. Lei, J.M. Musser and S.C. Tu, *Antimicrob. Agents Chemother.*, **47**, 670 (2003).
- G.P. Morlock, B. Metchock, D. Sikes, J.T. Crawford and R.C. Cooksey, *Antimicrob. Agents Chemother.*, **47**, 3799 (2003).
- L.P. Ormerod, *Br. Med. Bull.*, **73**, 17 (2005).
- S. Polanc, *Targets Heterocycl. Syst.*, **3**, 33 (1999); *Chem Abstr.*, **133**, 237877u (2000).
- M.M. Dutta, B.N. Goswami and J.C.S. Katak, *J. Heterocycl. Chem.*, **23**, 793 (1986).
- T.R. Opie, Preparation of Benzodioxin Carboxylic Acid Hydrazides as Insecticides, Eur. Pat. Appl. EP 984,009, 8 March, (2000); *Chem. Abstr.*, **132**, 194382 (2000).
- M.J. Broadhurst, W.H. Johnson and D.S. Walter, PCT Int. Appl. WO 00 35,885, 22 June (2000); *Chem. Abstr.*, **133**, 58802u (2000).
- H.L. Yale, K. Losee, J. Martins, M. Holsing, F.M. Perry and J. Bernstein, *J. Am. Chem. Soc.*, **75**, 1933 (1953).
- J. Bernstein, W.P. Jambor, W.A. Lott, F. Pansy, B.A. Steinberg and H.L. Yale, *Am. Rev. Tuberc.*, **67**, 366 (1953); *Chem. Abstr.*, **48**, 3551g (1954).
- L. Troeberg, X. Chen, T.M. Flaherty, R.E. Morty, M. Cheng, H. Hua, C. Springer, J.H. Mc Kerrow, G.L. Kenyon, J.D. Lonsdale-Eccles, T.H.T. Coetzer and F.E. Cohen, *Mol. Med. (NY)*, **6**, 660 (2000); *Chem. Abstr.*, **134**, 246896x (2001).
- P.H. Ermann and H. Straub, Heterocyclic Hydrazide Derivatives of Monocyclic β -Lactam Antibiotics, US Patent 5,318,963, 7 June (1994); *Chem. Abstr.*, **122**, 55819s (1995).
- P.N. Markham, E.A. Klyachko, D. Crich, M.R. Jaber, M.E. Johnson, D.C. Mulhearn and A.A. Neyfakh, PCT Int. Appl. WO 01 70, 213, 27 September (2001); *Chem. Abstr.*, **135**, 251941h (2001).
- A.K. Sengupta and A. Bhatnagar, *J. Indian Chem. Soc.*, **64**, 616 (1987).
- A.K. Mansour, M.M. Eid and N.S.A.M. Khalil, *Molecules*, **8**, 744 (2003).
- K. Waisser, J. Gregor, L. Kublcova, V. Klimesova, J. Kunes, M. Machacek and J. Kausrova, *Eur. J. Med. Chem.*, **35**, 733 (2000).
- A.S. Albogami, A.M. Almajid, M.A. Al-Saad, A.M. Mosa, S.A. Almazroa and H.Z. Alkhatlan, *Molecules*, **14**, 2147 (2009).
- T. Ishiwaka, M. Yonemoto, K. Isagaw, Y. Fushizaki and Y. Bull, *Chem. Soc. (Japan)*, **43**, 135 (1970).
- H.Z. Alkhatlan, *Tetrahedron*, **59**, 8163 (2003).
- H. Kohl, P.D. Desai, D. Dohadwalla and A.N. de Souza, *J. Pharm. Sci.*, **63**, 838 (1974).
- P. Molina, C. Conesa, A. Alias, A. Arques and M. Velasco, *Tetrahedron*, **49**, 7599 (1993).
- H.Z. Alkhatlan, *Synth. Commun.*, **34**, 71 (2004).
- H.Z. Alkhatlan, M.A. Al-Saad, H.M. Al-Hazimi, K.A. Al-Farhan and A.A. Mousa, *J. Chem. Res.*, **473S**, 1023(M) (2002).